Evaluation of the Anyplex BRAF V600E Real-Time Detection Assay Using Dual-Priming Oligonucleotide Technology in Fine-Needle Aspirates of Thyroid Nodules
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Several molecular assays have been developed to detect the BRAF V600E mutation in fine needle aspirates (FNAs) for the diagnosis of papillary thyroid cancer. Using a multiplex PCR technique, we evaluated the Anyplex BRAF V600E Real-time Detection (Anyplex) assay and compared its efficacy with that of the Seeplex BRAF V600E ACE Detection (Seeplex) method. Methods: We tested 258 consecutive FNA specimens using the Seeplex and Anyplex assays. Any conflicting results between the two assays were confirmed by using mutant enrichment with 3´-modified oligonucleotide (MEMO) sequencing. The limits of detection (LODs) and reproducibility for each assay were evaluated with serially diluted DNA from a BRAF V600E-positive cell line. Results: The BRAF V600E mutation was detected in 36.4% (94/258) FNA specimens by either the Seeplex or Anyplex assay. Results for the two assays showed 93.4% (241/258) agreement, with a kappa value of 0.861 (95% confidence interval, 0.798-0.923). Of the eight specimens that were BRAF V600E-positive by the Anyplex assay but not by the Seeplex assay, five were found to be BRAF V600E-positive by MEMO sequencing. The mutation detection rate of the Seeplex and Anyplex assays was 79.0% and 84.0%, respectively, in the FNA specimens diagnosed as malignant (n=81). The LOD as determined by probit analysis was 0.046% (95% confidence interval, 0.019-0.532%). Conclusions: The Anyplex assay performed better than the Seeplex assay with respect to the detection of the BRAF V600E mutation.
Abstract
Background: Several molecular assays have been developed to detect the BRAF V600E mutation in fine needle aspirates (FNAs) for the diagnosis of papillary thyroid cancer. Using a multiplex PCR technique, we evaluated the Anyplex BRAF V600E Real-time Detection (Anyplex) assay and compared its efficacy with that of the Seeplex BRAF V600E ACE Detection (Seeplex) method. Methods: We tested 258 consecutive FNA specimens using the Seeplex and Anyplex assays. Any conflicting results between the two assays were confirmed by using mutant enrichment with 3´-modified oligonucleotide (MEMO) sequencing. The limits of detection (LODs) and reproducibility for each assay were evaluated with serially diluted DNA from a BRAF V600E-positive cell line. Results: The BRAF V600E mutation was detected in 36.4% (94/258) FNA specimens by either the Seeplex or Anyplex assay. Results for the two assays showed 93.4% (241/258) agreement, with a kappa value of 0.861 (95% confidence interval, 0.798-0.923). Of the eight specimens that were BRAF V600E-positive by the Anyplex assay but not by the Seeplex assay, five were found to be BRAF V600E-positive by MEMO sequencing. The mutation detection rate of the Seeplex and Anyplex assays was 79.0% and 84.0%, respectively, in the FNA specimens diagnosed as malignant (n=81). The LOD as determined by probit analysis was 0.046% (95% confidence interval, 0.019-0.532%). Conclusions: The Anyplex assay performed better than the Seeplex assay with respect to the detection of the BRAF V600E mutation.
참고문헌 (20)
- Jemal A, "Global cancer statistics", CA Cancer J Clin, 61, pp.69~90 (2011)
- Xing M., "Molecular pathogenesis and mechanisms of thyroid cancer", Nat Rev Cancer, 13, pp.184~199 (2013)
- Millington GW, "Mutations of the BRAF gene in human cancer, by Davies et al. (Nature 2002; 417: 949-54)", Clin Exp Dermatol, 38, pp.222~223 (2013)
- Li C, "BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis", J Clin Endocrinol Metab, 97, pp.4559~4570 (2012)
- Lee JH, "Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis", Cancer, 110, pp.38~46 (2007)
- Rivera M, "Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns", Mod Pathol, 23, pp.1191~1200 (2010)
- Xing M, "BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer", J Clin Endocrinol Metab, 90, pp.6373~6379 (2005)
- Hertzman Johansson C, "BRAF inhibitors in cancer therapy", Pharmacol Ther, 142, pp.176~182 (2014)
- Nikiforov YE, "Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules", J Clin Endocrinol Metab, 94, pp.2092~2098 (2009)
- Kim SW, "BRAF V600E mutation analysis in fine-needle aspiration cytology specimens for evaluation of thyroid nodule: a large series in a BRAF V600E-prevalent population", J Clin Endocrinol Metab, 95, pp.3693~3700 (2010)
- Poller DN, "New technology in thyroid fine-needle aspiration", J Clin Pathol, 67, pp.457~ (2014)
- Lee ST, "Clinical implication of highly sensitive detection of the BRAF V600E mutation in fine-needle aspirations of thyroid nodules: a comparative analysis of three molecular assays in 4585 consecutive cases in a BRAF V600E mutation-prevalent area", J Clin Endocrinol Metab, 97, pp.2299~2306 (2012)
- Dyhdalo K, "Assessment of cellularity, genomic DNA yields, and technical platforms for BRAF mutational testing in thyroid fine-needle aspirate samples", Cancer Cytopathol, 122, pp.114~122 (2014)
- Milbury CA, "PCR-based methods for the enrichment of minority alleles and mutations", Clin Chem, 55, pp.632~640 (2009)
- Lee ST, "Mutant enrichment with 3´-modified oligonucleotides a practical PCR method for detecting trace mutant DNAs", J Mol Diagn, 13, pp.657~668 (2011)
- Baloch ZW, "Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference", Diagn Cytopathol, 36, pp.425~437 (2008)
- Kwak JY, "Dual priming oligonucleotide-based multiplex PCR analysis for detection of BRAFV600E mutation in FNAB samples of thyroid nodules in BRAF V600E mutation-prevalent area", Head Neck, 32, pp.490~498 (2010)
- Landis JR, "The measurement of observer agreement for categorical data", Biometrics, 33, pp.159~174 (1977)
- Kwak JY, "BRAF V600E mutation testing in fine needle aspirates of thyroid nodules: potential value of real-time PCR", Ann Clin Lab Sci, 42, pp.258~265 (2012)
- Forbes SA, "The Catalogue of Somatic Mutations in Cancer (COSMIC)", Curr Protoc Hum Genet (2008)